{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:08:20Z","timestamp":1785186500759,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1124\/jpet.111.181255","type":"journal-article","created":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T02:38:47Z","timestamp":1303785527000},"page":"381-391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Bulky N(6) Substituent of Cabergoline Is Responsible for Agonism of This Drug at 5-Hydroxytryptamine (5-HT)2A and 5-HT2B Receptors and Thus Is a Determinant of Valvular Heart Disease"],"prefix":"10.1016","volume":"338","author":[{"given":"Alexandra","family":"Kekewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gmeiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz H.","family":"Pertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.111.181255_bib1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1474-4422(07)70218-1","article-title":"Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson\u2019s disease","volume":"6","author":"Antonini","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1124\/jpet.111.181255_bib2","first-page":"626","article-title":"Organ culture as a tool to identify early mechanisms of serotonergic valve disease","volume":"19","author":"Barzilla","year":"2010","journal-title":"J Heart Valve Dis"},{"key":"10.1124\/jpet.111.181255_bib3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3109\/00498259309059447","article-title":"Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man","volume":"23","author":"Battaglia","year":"1993","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.111.181255_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(09)60252-X","article-title":"Drug-induced fibrotic valvular heart disease","volume":"374","author":"Bhattacharyya","year":"2009","journal-title":"Lancet"},{"key":"10.1124\/jpet.111.181255_bib5","first-page":"822","article-title":"Influence of 5-hydroxytryptamine on aortic valve competence in vitro","volume":"10","author":"Chester","year":"2001","journal-title":"J Heart Valve Dis"},{"key":"10.1124\/jpet.111.181255_bib6","first-page":"250","article-title":"Receptor-mediated contraction of aortic valve leaflets","volume":"9","author":"Chester","year":"2000","journal-title":"J Heart Valve Dis"},{"key":"10.1124\/jpet.111.181255_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1098\/rstb.2007.2126","article-title":"Molecular and functional characteristics of heart-valve interstitial cells","volume":"362","author":"Chester","year":"2007","journal-title":"Phil Trans R Soc B"},{"key":"10.1124\/jpet.111.181255_bib8","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.111.181255_bib9","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2353\/ajpath.2009.081101","article-title":"Fenfluramine disrupts the mitral valve interstitial cell response to serotonin","volume":"175","author":"Connolly","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.111.181255_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.181255_bib11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/sj.bjp.0703341","article-title":"Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT2B receptors","volume":"130","author":"Glusa","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.111.181255_bib12","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1124\/jpet.107.133165","article-title":"Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-hydroxytryptamine2B and 5-hydroxytryptamine2A receptors","volume":"324","author":"G\u00f6rnemann","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.181255_bib13","first-page":"920","article-title":"Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line","volume":"6","author":"Hayes","year":"1992","journal-title":"Mol Endocrinol"},{"key":"10.1124\/jpet.111.181255_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00002826-200603000-00005","article-title":"Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis","volume":"29","author":"Hofmann","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/jpet.111.181255_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0165-6147(93)90129-8","article-title":"Partial agonists, full agonists, antagonists: dilemmas of definition","volume":"14","author":"Hoyer","year":"1993","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.111.181255_bib16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1124\/mol.109.058057","article-title":"Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment","volume":"76","author":"Huang","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.181255_bib17","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1016\/j.bmcl.2005.07.024","article-title":"Synthesis of potent and selective serotonin 5-HT1B receptor ligands","volume":"15","author":"Huang","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.111.181255_bib18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1021\/jm991098z","article-title":"Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D3 subtype","volume":"43","author":"H\u00fcbner","year":"2000","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.111.181255_bib19","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0002-9440(10)64489-6","article-title":"Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-\u03b21 via G-protein signal transduction in aortic valve interstitial cells","volume":"161","author":"Jian","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.111.181255_bib20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-08-0611","article-title":"Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required","volume":"159","author":"Kars","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1124\/jpet.111.181255_bib21","series-title":"Pharmacological Analysis of Drug-Receptor Interaction","author":"Kenakin","year":"1993"},{"key":"10.1124\/jpet.111.181255_bib22","first-page":"798","article-title":"Specific regional and directional contractile responses of aortic cusp tissue","volume":"13","author":"Kershaw","year":"2004","journal-title":"J Heart Valve Dis"},{"key":"10.1124\/jpet.111.181255_bib23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00210-008-0378-4","article-title":"Pharmacological characterization of mitogen-activated protein kinase activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors","volume":"379","author":"Knauer","year":"2009","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.111.181255_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2202-9-85","article-title":"Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK\/ERK pathway","volume":"9","author":"Maddahi","year":"2008","journal-title":"BMC Neurosci"},{"key":"10.1124\/jpet.111.181255_bib25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0022-3565(25)30624-5","article-title":"On the statistics of drug-receptor constants for partial agonists","volume":"198","author":"Marano","year":"1976","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.181255_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCULATIONAHA.105.554667","article-title":"Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice","volume":"113","author":"Mekontso-Dessap","year":"2006","journal-title":"Circulation"},{"key":"10.1124\/jpet.111.181255_bib27","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/BF02026491","article-title":"Venoconstrictor responses to dihydroergocristine and dihydroergotamine: evidence for the involvement of 5-HT1 like receptors","volume":"4","author":"M\u00fcller-Schweinitzer","year":"1990","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1124\/jpet.111.181255_bib28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/jpet.102.039875","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and \u03b11\/\u03b12-adrenoceptor","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.181255_bib29","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1, and 5-HT2, receptor subtypes","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 18","key":"10.1124\/jpet.111.181255_bib30","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1002\/mds.21545","article-title":"State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome","volume":"22","author":"Oertel","year":"2007","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.111.181255_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.111.181255_bib32","first-page":"256","article-title":"Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves","volume":"9","author":"Roy","year":"2000","journal-title":"J Heart Valve Dis"},{"key":"10.1124\/jpet.111.181255_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.carpath.2005.03.005","article-title":"Cardiac valves and valvular pathology: update on function, disease, repair, and replacement","volume":"14","author":"Schoen","year":"2005","journal-title":"Cardiovasc Pathol"},{"key":"10.1124\/jpet.111.181255_bib34","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/jm050170s","article-title":"Fancy bioisosteres: metallocene-derived G-protein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles","volume":"48","author":"Schlotter","year":"2005","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.111.181255_bib35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00045415-200211000-00005","article-title":"Fibrotic valvular heart disease subsequent to bromocriptine treatment","volume":"10","author":"Serratrice","year":"2002","journal-title":"Cardiol Rev"},{"key":"10.1124\/jpet.111.181255_bib36","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","article-title":"3,4-Methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro","volume":"63","author":"Setola","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.181255_bib37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2265.2010.03827.x","article-title":"Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia","volume":"73","author":"Tan","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1124\/jpet.111.181255_bib38","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/S0002-9440(10)64497-5","article-title":"Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells","volume":"161","author":"Xu","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.111.181255_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.14797\/mdcvj.186","article-title":"The role of cell biology and leaflet remodeling in the progression of heart valve disease","volume":"6","author":"Xu","year":"2010","journal-title":"Methodist Debakey Cardiovasc J"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524464604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524464604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.111.181255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:32:40Z","timestamp":1740018760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524464604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0022356524464604"],"URL":"https:\/\/doi.org\/10.1124\/jpet.111.181255","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Bulky N(6) Substituent of Cabergoline Is Responsible for Agonism of This Drug at 5-Hydroxytryptamine (5-HT)2A and 5-HT2B Receptors and Thus Is a Determinant of Valvular Heart Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.111.181255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}